<DOC>
	<DOCNO>NCT00936715</DOCNO>
	<brief_summary>The objective study provide open label emtricitabine/tenofovir disoproxil fumarate ( DF ) additional 5 year subject complete study GS-US-203-0107 .</brief_summary>
	<brief_title>Rollover Protocol Continued Access Emtricitabine/Tenofovir Disoproxil Fumarate Subjects United States</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Complete end study visit procedure PK substudy ( applicable ) GS US 203 0107 study . A negative pregnancy test require female subject end study visit GS US 203 0107 ( unless surgically sterile great two year postmenopausal ) . All sexually active female subject post menopausal , surgically sterile childbearing potential must agree use highly effective method contraception heterosexual intercourse throughout study . Male subject sexually active require use barrier contraception ( condom spermicide ) heterosexual intercourse study completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>prevention chronic hepatitis B recurrence</keyword>
	<keyword>post orthotopic liver transplant</keyword>
	<keyword>Prevention chronic hepatitis B recurrence patient undergone orthotopic liver transplant</keyword>
</DOC>